GleamWall
中文EN

HBIO HARVARD BIOSCIENCE INC

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1123494 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.3%
TTM net income YoY78.1%
TTM EPS YoY173.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR—

Margins

Gross margin57.4%
Operating margin-1.8%
Net margin-13.2%
FCF margin-3.5%
EBITDA margin0.3%

Returns

ROE-123.1%
ROA-15.4%
ROIC (approx.)-3.2%
Asset turnover1.17x

Leverage & solvency

Liabilities / assets93.2%
Debt / equity7.28x
Current ratio1.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$22.20M$22.73M$20.75M$23.73M$20.59M$20.45M$21.77M$24.56M
Cost of revenue$9.89M$10.10M$8.51M$9.56M$8.57M$8.92M$9.59M$10.54M
Gross profit$12.31M$12.63M$12.24M$14.17M$12.02M$11.53M$12.18M$14.01M
R&D expense$2.26M$2.45M$2.33M$2.18M$2.13M$2.19M$2.32M$2.33M
SG&A expense$4.76M$4.62M$4.70M$4.12M$4.18M$4.26M$5.18M$4.80M
Operating income-$1.15M-$978,000-$1.17M$1.71M$197,000-$819,000-$49.67M$11,000
Interest expense$1.30M$1.30M—$1.00M$1.00M$800,000——
Pretax income-$2.69M-$2.90M-$3.31M-$3.20M-$1.13M-$2.25M-$50.79M$590,000
Income tax-$72,000$14,000$117,000-$357,000$97,000$28,000-$454,000$572,000
Net income-$2.62M-$2.91M-$3.42M-$2.85M-$1.23M-$2.28M-$50.34M$18,000
EBITDA-$650,000-$511,000-$731,000$2.17M$622,000-$408,000-$49.22M$470,000
EPS (basic)-0.58-0.64-0.77—-0.28-0.52-11.42—
EPS (diluted)-0.58-0.64-0.77—-0.28-0.52-11.42—
Weighted avg. shares (diluted)4.56M4.53M4.47M—4.46M4.43M4.41M—
Balance sheet
Cash & equivalents$4.86M$6.50M$7.10M$8.61M$6.82M$7.44M$5.55M$4.11M
Receivables$14.91M$14.50M$14.57M$16.04M$12.11M$11.94M$13.48M$14.87M
Inventory$23.49M$22.23M$22.20M$20.80M$21.60M$22.25M$22.82M$23.25M
Current assets$45.98M$46.46M$47.48M$48.23M$43.80M$44.97M$44.90M$45.12M
PP&E, net$5.40M$5.35M$4.87M$4.79M$4.99M$4.91M$5.01M$5.11M
Goodwill$9.30M$9.33M$9.37M$9.56M$9.53M$10.15M$8.96M$56.32M
Intangibles$6.18M$6.22M$6.91M$7.64M$8.38M$9.14M$10.13M$11.13M
Total assets$75.30M$76.29M$77.94M$80.07M$77.99M$80.09M$79.80M$126.64M
Current liabilities$26.13M$24.79M$23.86M$21.96M$54.40M$55.20M$55.60M$54.96M
Short-term debt$0$0$0$0———$36.96M
Long-term debt$37.15M$36.68M$36.21M$35.87M$33.97M$34.90M$36.40M$0
Total debt$37.15M$36.68M$36.21M$35.87M$33.97M$34.90M$36.40M$36.96M
Total liabilities$70.19M$68.87M$67.89M$66.34M$63.92M$64.36M$64.97M$63.30M
Shareholders' equity$5.11M$7.42M$10.05M$13.73M$14.07M$15.73M$14.84M$63.34M
Net debt$32.30M$30.18M$29.11M$27.26M$27.15M$27.46M$30.85M$32.85M
Shares outstanding4.57M4.55M4.51M4.47M44.58M44.53M44.21M44.07M
Cash flow statement
Operating cash flow-$248,000$325,000-$662,000-$96,000$1.08M$2.75M$2.99M$1.73M
Capital expenditure$927,000$688,000$426,000$449,000$207,000$89,000$513,000$301,000
Free cash flow-$1.18M-$363,000-$1.09M-$545,000$877,000$2.67M$2.47M$1.42M
Investing cash flow-$1.34M-$916,000-$620,000-$599,000-$348,000-$233,000-$683,000-$466,000
Financing cash flow-$45,000-$38,000-$9,000$2.45M-$1.28M-$1.26M-$1.20M-$1.36M
Depreciation & amortization$500,000$467,000$443,000$456,000$425,000$411,000$451,000$459,000
Stock-based compensation$436,000$380,000$257,000$459,000$324,000$472,000$600,000$961,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.